Ital J Gastroenterol. 1991 May;23(4):175-8.

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

Pedretti G, Calzetti C, Missale G, Fiaccadori F.

Source

Cattedra di Malattie Infettive, Università di Parma, Italy.

Abstract

Preliminary data suggest that rifaximin a new non-absorbable rifamycin-derivate, has beneficial effects on chronic portal systemic encephalopathy (PSE). To compare the efficacy and safety of rifaximin vs neomycin in the treatment of the hyperammoniemic state of PSE, 30 cirrhotic patients with grade I to III of PSE were randomly allocated to one of two groups: group A (15 patients) receiving rifaximin (400 mg/8h) and group B (15 patients) neomycin (1gr/8h). The duration of treatment was 21 consecutive days. Age, sex, hepatic and renal function, level of PSE, EEG and number connection test were similar in both groups. A significant decrease in blood ammonia levels was observed at the end of the treatment period in both groups; moreover rifaximin produced an earlier reduction of blood ammonia levels. The neuropsychic syndrome related to the PSE improved in both groups without significant difference. No side effects attributable to therapy were observed in the rifaximin group. These results indicate that, rifaximin is at least as effective as neomycin in the achievement and maintenance of low blood ammonia levels in cirrhotics with chronic PSE.

PMID:: 1751811; [PubMed - indexed for MEDLINE]

LinkOut - more resources

Medical

Cirrhosis - MedlinePlus Health Information

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial. [Curr Med Res Opin. 1997]
Rifaximin, a non-absorbable rifamycin, for the treatment of hepatic encephalopathy. A double-blind, randomised trial.
Miglio F, Valpiani D, Rossellini SR, Ferrieri A. Curr Med Res Opin. 1997; 13(10):593-601.
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. [J Hepatol. 2003]
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial.
Mas A, Rodés J, Sunyer L, Rodrigo L, Planas R, Vargas V, Castells L, Rodríguez-Martínez D, Fernández-Rodríguez C, Coll I, et al. J Hepatol. 2003 Jan; 38(1):51-8.
Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study. [Eur J Gastroenterol Hepatol. 2...]
Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
Williams R, James OF, Warnes TW, Morgan MY. Eur J Gastroenterol Hepatol. 2000 Feb; 12(2):203-8.
Review Rifaximin for the treatment of hepatic encephalopathy. [Am J Health Syst Pharm. 2008]
Review Rifaximin for the treatment of hepatic encephalopathy.
de Melo RT, Charneski L, Hilas O. Am J Health Syst Pharm. 2008 May 1; 65(9):818-22.
Review Rifaximin for treatment of hepatic encephalopathy. [Ann Pharmacother. 2009]
Review Rifaximin for treatment of hepatic encephalopathy.
Maclayton DO, Eaton-Maxwell A. Ann Pharmacother. 2009 Jan; 43(1):77-84. Epub 2008 Dec 17.

See reviews... See all...

Cited by 3 PubMed Central articles

Review Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis. [World J Gastroenterol. 2012]
Review Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
Eltawil KM, Laryea M, Peltekian K, Molinari M. World J Gastroenterol. 2012 Feb 28; 18(8):767-77.
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence. [Therap Adv Gastroenterol. 2011]
Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.
Flamm SL. Therap Adv Gastroenterol. 2011 May; 4(3):199-206.
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. [Yonsei Med J. 2005]
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
Paik YH, Lee KS, Han KH, Song KH, Kim MH, Moon BS, Ahn SH, Lee SJ, Park HJ, Lee DK, et al. Yonsei Med J. 2005 Jun 30; 46(3):399-407.

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Compound (MeSH Keyword)
PubChem chemical compound records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Substance (MeSH Keyword)
PubChem chemical substance (submitted) records that are classified under the same Medical Subject Headings (MeSH) controlled vocabulary as the current articles.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephal...
Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.
Ital J Gastroenterol. 1991 May ;23(4):175-8.

PubMed
Learning-based segmentation framework for tissue images containing gene expressi...
Learning-based segmentation framework for tissue images containing gene expression data.
IEEE Trans Med Imaging. 2007 May ;26(5):728-44.

PubMed
Developing mathematical models of neurobehavioral performance for the "real worl...
Developing mathematical models of neurobehavioral performance for the "real world".
J Biol Rhythms. 2007 Jun ;22(3):246-58.

PubMed
A ubiquitin-binding motif in the translesion DNA polymerase Rev1 mediates its es...
A ubiquitin-binding motif in the translesion DNA polymerase Rev1 mediates its essential functional interaction with ubiquitinated proliferating cell nuclear antigen in response to DNA damage.
J Biol Chem. 2007 Jul 13 ;282(28):20256-63. Epub 2007 May 21 .

PubMed
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate o...
The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.
J Biol Chem. 2007 Jul 13 ;282(28):20329-39. Epub 2007 May 21 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to:

Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial.

Source

Abstract

Publication Types, MeSH Terms, Substances

Publication Types

MeSH Terms

Substances

LinkOut - more resources

Medical

Molecular Biology Databases

Supplemental Content

Save items

Related citations in PubMed

Cited by 3 PubMed Central articles

Related information

Recent activity

Simple NCBI Directory

Getting Started

Resources

Popular

Featured

NCBI Information